Study Phase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV

Trial Information

Generic NameAd26.RSV.preFProduct NameN/ATherapeutic AreaAnti-Infectives for Systemic UseProduct ClassVaccinesPharmacological SubgroupViral VaccinesChemical SubgroupOther Viral VaccinesCondition StudiedRespiratory Syncytial Viruses
Sponsor Protocol NumberVAC18193RSV3006Enrollment1124Data PartnerJohnson & Johnson% Female58.0%Mean/Median Age (Years)50.6% White94.9%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.